A few questions were posed to PI Prof Dr Donato (Dino) DiMonte to gain his views on his work in Parkinson research and PD-MitoQUANT, in general. Dino is a senior researcher and leads the Neurodegeneration and Neuroprotection in Parkinson’s Disease Group at the German Center for Neurodegenerative Diseases (DZNE). Please describe your day to day work. It is difficult to describe a “typical” day of work. Most of the time, our working schedule involves specific tasks that vary from day to day and often have specific deadlines. For example, there are deadlines to apply for research grants, to complete research reports, to submit and review manuscripts and to perform administrative and educational duties. There are also commitments that, albeit quite regular, may not be part of a “daily” routine. These include attendance at research seminars, conference calls with research collaborators and participation in scientific meetings organized “in house” or requiring [...]
The 5th World Parkinson Congress (WPC) was held in Kyoto, Japan from June 4– 7, 2019. More than 3,000 people from more than 60 countries attended the meeting. At this meeting, Dr Ronald Melki of the Centre National de la Recherche Scientifique (CNRS) and PD-MitoQUANT PI presented: "What is alpha-synuclein- The biology". Through Ronald's talk, PD-MitoQUANT funding was acknowledged. Dr Ronald Melki, CNRS at WPC 2019 The WPC 2019 hosted an international, interdisciplinary forum showcasing the most important developments in the world of Parkinson's. As medical advances continue to accelerate, the goal of the WPC is to advance an all-encompassing approach to the treatment of Parkinson’s by bringing together the full spectrum of those who serve the Parkinson’s community. These will include representatives of professional medical and scientific organizations; nurses and rehabilitation professionals; voluntary, lay, and patient services organizations; the pharmaceutical industry; and the research and health services [...]
Beckie Port "From innovation to better treatments" is the title of a blog post published on 27 May 2019 by Dr Beckie Port. Beckie is Research Communications Manager at PD-MitoQUANT partner Parkinson's UK. This blog entry announces partnerships with two pan-European, IMI-funded research projects: PD-MitoQUANT and Neuronet. In it, Beckie describes how these collaborative projects aim to accelerate research and deliver new treatments for Parkinson’s. Read the full blog post here.
PD-MitoQUANT PI Ronald Melki of the Centre National de la Recherche Scientifique (CNRS) recently delivered the plenary lecture of the Frontiers in Neuroscience session of the American Academy of Neurology (AAN) annual meeting on May 8, 2019, in Philadelphia, USA. Through his talk, PD-MitoQUANT funding was acknowledged. More than 3000 were in attendance. The theme of the 71st AAN annual meeting was "Advancing Neurology, Advancing You". It was held May 4- 10th. The meeting offers unparalleled opportunities for professional and personal advancement at the world’s largest gathering of neurologists and neurology professionals. Read the abstracts from the 2019 AAN meeting here.
PD-MitoQUANT recently appeared in the news stream of HealthEuropa.eu. Read the story, “The Innovative Medicines Initiative, mitochondrial dysfunction and Parkinson’s". Read the story here. Health Europa highlights the latest trends and developments in health and healthcare from across Europe. Their platform is a valuable news source to the health sector, allowing them to discuss research and innovation themes, health policy and new technologies. In addition, the website, HealthEuropa.eu has gained Google News approval. It features news, interviews and insightful commentary from leading figures, keeping readers informed and up to date on all aspects of health and care.